Abstract: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

Abstract: A method for cleaving amide bonds, comprising: a) providing a molecule comprising an amide group; b) reacting the molecule comprising an amide group with hydroxylamine (NH2OH) or a salt thereof to cleave the amide bond of the amide group.

Abstract: The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travelers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal.

Abstract: The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.

Abstract: Compositions containing free amino acids have been found to provide effective pain relief in less than five minutes following administration. Suitable compositions include free leucine, free isoleucine, and free valine in a leucine:isoleucine:valine weight ratio of about 1.9:1:1.3. Palatability is improved by the addition of free glycine, such that sweeteners or other flavorants are not necessary. The composition can be a two part formulation in which certain amino acids are provided as a capsule or tablet in order to improve palatability.

Abstract: Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.

Abstract: This invention relates generally to compositions and methods for combating inflammatory disease and particularly to the use of food and/or feed compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts, wherein the compositions comprising at least one specific pectin.

Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Abstract: An object of the present invention is to provide a crystal of 3?-sialyllactose (hereinafter, referred to as 3SL), which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a process for producing the same. The present invention relates to a 3SL sodium salt n-hydrate (wherein n represents any number of 0 to 9, and when n is 0, it is referred to as 3SL sodium salt anhydrate) and a process for producing the same.

Abstract: A cosmetic or dermocosmetic agent consisting of galactomannans with molecular masses in a range from 1 to 150 kDa obtained from Caesalpinia spinose and cross-linked sulfated galactans with molar masses in a range from 1 to 150 kDa obtained from Kappaphycus alvarezii. Non-therapeutic cosmetic methods in which the agent is applied on the skin in order to tens the skin and/or to form a film on the skin.

Abstract: The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.

Abstract: A system, method, and apparatus for treating a tissue site with reduced pressure includes a dressing adapted to be positioned proximate the tissue site. An absorbent may be adapted to be fluidly coupled to the manifold, and an ion exchange member may be adapted to be fluidly coupled between the manifold and the absorbent. A sealing member may be adapted to cover the tissue site to form a sealed space having the manifold disposed therein. A reduced-pressure source may be adapted to be fluidly coupled to the manifold.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.

Abstract: Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.

Abstract: Provided in accordance with the present disclosure is a diagnostic and a therapeutic bronchoscopy system for localized delivery of medication within the lungs. Specifically, systems and methods are disclosed for creating a functional and anatomical map of the lungs, diagnosing a condition within the lungs, generating a treatment plan for a target site within the lungs, navigating to the target site, administering a treatment directly to the target site for immediate absorption within the target site, and assessing the efficacy of the treatment.

Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.

Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycelium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.

Abstract: The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid.

Abstract: The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis C.

Abstract: A method of treating skin in need thereof is disclosed. The method can include topically applying to the skin a composition consisting of kakadu plum extract, glycerin, water, and optionally alcohol.

Abstract: A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment, of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.

Abstract: An oxidized ?-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. By using abundant cellulose in the natural world as the raw material, all 6-site hydroxyl groups of the cellulose ?-1,4-polyglucose is oxidized into carboxyl groups to form glucuronic acid under the action of a sodium bromide (NaBr)-2,2,6,6-tetramethyl piperidine oxide (TEMPO)-sodium hypochlorite (NaClO) oxidation system, and the oxidized oligoglucuronic acid having an open ring at an end is prepared by controlling reaction conditions. The compound has obvious anti-cerebral ischemia activity, and can be developed into a potential anti-cerebral ischemia drug.

Abstract: Methods for producing refined xylan from a biomass solution, including: (i) providing a biomass solution, which comprises xylan; (ii) concentrating or separating said biomass solution to obtain a xylan concentrate comprising xylan and impurities; (iii) washing and/or extracting the xylan concentrate with a solvent to obtain refined xylan and a solvent stream comprising the solvent and impurities; and (iv) collecting the refined xylan.

Abstract: The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation.

Abstract: The present application provides a method of increasing relative abundance of Oscillospira in gastro-intestinal tract of a subject. The method comprising administering to said subject at least 2.5 g per day of fructo-oligosaccharide, such that the abundance of Oscillospira is increased to a statistically significant level when measured by F-test. A composition for increasing relative abundance of Oscillospira in gastro-intestinal tract of a subject is also disclosed.

Abstract: Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from Euglena, which provides a form of beta glucan that is different from other organisms, where the beta glucan is predominantly unbranched beta-(1,3)-glucan. Beta glucan can also be complexed with a metal, such as zinc, and/or can combined with an animal feed component to form an animal feed composition. Use of such compositions can improve the well being of an animal, and may augment or even replace the use of antibiotics in certain circumstances.

Abstract: The present invention provides a rocuronium preparation with an excellent stability. The rocuronium preparation contains rocuronium and a buffer solution and having an adjusted pH of 3.5 or less (for example, 2.5 to 3.5). The buffer solution may be a citric acid-sodium hydroxide buffer solution, a tartaric acid-sodium hydroxide buffer solution, a potassium hydrogen phthalate-hydrochloric acid buffer solution, a glycine-hydrochloric acid buffer solution, or the like. Such a rocuronium preparation has, for example, after 6-month storage at 40° C., a generation rate of rocuronium-related substance C of 5% or less.

Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.

Abstract: The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.

Abstract: Described herein are methods of producing animal feed made up of oligosaccharide compositions, as well as methods of producing such oligosaccharide compositions and animal feed compositions, and methods of using such animal feed compositions to enhance animal growth.

Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

Abstract: A method to process microalgae biomass and produce high-value chemicals from microalgae biomass is disclosed. The method uses the same biomass cells to extract more than one component such as lipids, water-soluble chemicals, carotenoids, polysaccharides and algae meal. The method is a sequence of physical and chemical treatments. Water soluble polysaccharides produced by the method exhibit properties of low viscosity at low shear thinning. A method for extracting dietary fiber from microalgal biomass is disclosed. Compositions of water-soluble polysaccharides that are fermented slowly by colon microbiota with less gas production than commercial dietary fiber FOS are disclosed. The present inventions described herein provide a method of improving colon health by increasing butyrate during a microalgal dietary fiber fermenting process by colonic microbiota.

Abstract: The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

Abstract: Compositions, specifically a jelly, are provided the use of which composition as an auxiliary means eases the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm.

Abstract: The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is a hydrolyzed pea protein based nutrient composition for use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein hydrolysates, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.

Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Abstract: Methods of making polycationic nanofibers by grafting cationic polymers onto electrospun neutral nanofibers and polycationic nanofibers produced by the methods are provided herein. In addition, methods of using the polycationic nanofibers to reduce inflammation, to adsorb anionic compounds such as heparin or nucleic acids, to inhibit the growth of microbes or inhibit the formation of a biofilm are also provided. The polycationic nanofibers may be in a mesh and may be included in a medical device, wound dressing, bandage, or as part of a graft.

Abstract: A method for enhancing an individual's mucosal innate immune response to pathogens is disclosed. The method includes a step of administering a nutritional composition to the individual. The nutritional composition includes about 0.05 to about 0.5 mg/mL 2?-fucosyllactose (2?-FL), about 0.05 to about 0.5 mg/mL lacto-N-neotetraose (LNnT), or a combination of both. Also disclosed is a method for enhancing an individual's mucosal innate immune detection of pathogens. The method includes a step of administering a nutritional composition to the individual. The nutritional composition includes a neutral human milk oligosaccharide.

Abstract: The present disclosure relates generally to the field of anti-viral therapy and prophylaxis. Formulations and agents are provided which inhibit viruses of the Orthomyxoviridae family and ameliorate symptoms and conditions caused by viral infection. The present disclosure teaches the control of influenza virus infection and spread and amelioration of conditions caused thereby. The formulations and agents may be processed as medicaments or as health supplements for more general application such as in the form of consumer goods or consumer foods.

Abstract: Compositions comprising extracts from marine organisms show beneficial effects on skin ailments. Fine lines, wrinkles, and sagging in skin are improved with the application of compositions with marine extracts. Production of collagen, elastin and hyaluronic acid are increased after application of the compositions.

Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).

Abstract: Disclosed is a prebiotic composition comprising a combination of 2?fucosyllactose (2?FL) and isomaltooligosaccharide (IMO). The 2?FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and/or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and/or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal.

Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

Abstract: The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.

Abstract: The present invention provides a facile method for separation (fractionation) of HA in a sample over a broad M range, including low M HA, by ion exchange (IEX) chromatography. The present invention also provides an assay method for quantifying in a sample the presence of low M HA in total HA isolated from a biological source. The method involves HA fractionation according to M by use of IEX separation, followed by HA-specific assay of HA size range fractions.

Abstract: The present specification generally relates to an injectable dermal filler composition that includes crosslinked hyaluronic acid-based polymer and an antioxidant.

Abstract: Disclosed is the adaptogenic activity of boswellic acids-polysaccharide compositions derived from Boswellia serrata in combination with either (i) the concentrate of the liquid endosperm of Cocos nucifera or (ii) the extract of Emblica officinalis fruit standardized to contain 10% w/w and above of 1-O-galloyl-?-D-glucose (?-glucogallin).